Select Committee on Home Affairs Minutes of Evidence


Examination of Witnesses (Questions 900 - 910)

TUESDAY 18 DECEMBER 2001

PROFESSOR JUERGEN REHM AND DR GERRIT VAN SANTEN

Angela Watkinson

  900. Could I ask how the treatment is funded? Is it totally tax funded or if the addict has an income is there any cost to the addict or is it through health insurance?
  (Dr van Santen) It is paid by health insurance. During the experiment, of course, it is paid by the government out of health insurance but normally addiction treatment is within health insurance.

  901. Through the general national health insurance that people pay via their income if they are in employment?
  (Dr van Santen) I think it would be too complicated to explain to you the Dutch health system.
  (Professor Rehm) Switzerland is a more capitalistic country and we do not have a public health system. There is provision, however, so that nobody falls between the cracks. But the addicts, for example, have to pay for certain things like heroin themselves.

Chairman

  902. They pay for the substance?
  (Professor Rehm) They pay for the substance but not for the care.

  903. Finally, gentlemen, are either of you familiar with the Swedish approach to drug addiction?
  (Professor Rehm) Sure.

  904. They say their objective is to have a totally drug free country and they believe they are making progress towards that end. Do you agree with them?
  (Professor Rehm) Have you seen a drug free society in the last 3,000 years?

  905. Even they are not pretending that their country is drug free; they just say that their approach, as I understand it (and I may be wrong) is that total repression does work.
  (Professor Rehm) Clearly they have a totally different system. On the other hand, it is true, according to our own calculations, that every litre of beer drunk in Sweden is causing four-fold risk of accidents or violence compared to a litre of beer drunk in Switzerland, France or Italy. It has to do with bingeing and with certain modes of drug taking and that is one example, alcohol. I think the question we are trying to solve is not to become a drug free society but to minimise all the harms to society by drugs and those are, of course, harms to the user but also harms to the general public, and looking at the burden from drugs and illicit drugs and alcohol, it is questionable that they have made progress in the last ten years. This is a scientific debate and this is clearly one position within a scientific debate. I go there quite often, there are lots of discussions on that. I could name you persons who have a different opinion on that but I think overall, once you change the perspective to saying "in our country there are less people using X or Y than your country," and you go into how much burden is actually created, Sweden is not making so much progress, but they are still on a comparatively low level in Europe. I do not think that is disputed by anybody.

  906. Thank you. You have visited Sweden on a number of occasions?
  (Professor Rehm) Yes we have comparative projects with Sweden and even though we are only an associate to the European Union we are allowed to get European money for research, and one of the projects is to compare the drug treatment systems in eight European countries.

  907. And how do they deal with heroin use? Do they have any experiments of the sort you have in Holland?
  (Professor Rehm) They have methadone and especially in the Karolinska Institute and the big cities they have methadone, and then they have a whole system of coercive abstinence-based treatments. They have certain other drug problems, for example they have not a lot of cocaine but they have way more amphetamines and you have to look at the overall picture.

  908. Dr van Santen?
  (Dr van Santen) I have not much to add to this. What you see everywhere is when there is a difference in policy you find first more agreement amongst professionals because they work with evidence based effective treatment, and the question is can you withhold from people effective treatment. What you see in Sweden is that development towards acceptance of these forms of treatment, which you have seen in Germany also.

  909. So you believe the Swedes are moving, despite their public rhetoric, towards the kind of experiments you are carrying out in Holland?
  (Dr van Santen) Because of the convincing evidence.
  (Professor Rehm) They have way too many overdoses for their estimates of drug users so something must be wrong in terms of harm. If you have only so many drug users then you cannot say that so many out of every 100 of them gets into an overdose. Something must be wrong, either the estimates of the drug users. The overdose is a hard fact. You can manipulate the definition but that is pretty hard and that is a death and overall those indicators are not that good. That is what I am saying about harm indicators. In professional settings, if you go into the Utrecht marijuana conference last week the Swedes had a big rhetoric, "we are against, we are against" but it if you go to the professionals two days later they say we have opened this, we have experimented with methadone, we have done this. so it is a little bit ambiguous.
  (Dr van Santen) It is interesting to know that a Swedish researcher did some investigation on mortality and compared the mortality from his small methadone programme to mortality among people on his waiting list and found that it was ten-fold higher. These are the facts of life which you cannot avoid.

  910. You think their figures may not stand up to scrutiny, their public figures?
  (Professor Rehm) No, the waiting list had a ten times higher mortality. And that is what is driving other professionals into doing methadone treatment, even though it is against the official ideology.

  Chairman: Thank you very much indeed. That has been extremely helpful and we are extremely grateful to you for coming to see us. This session is closed.





 
previous page contents

House of Commons home page Parliament home page House of Lords home page search page enquiries index

© Parliamentary copyright 2002
Prepared 22 May 2002